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 Expression and Possible Prognostic Role of MAGE-A4, NY-ESO-1, 
and HER-2 Antigens in Women with Relapsing Invasive Ductal Beast 
Cancer: Retrospective Immunohistochemical Study
Aim To evaluate the possible prognostic role of the expression of MAGE-
A4 and NY-ESO-1 cancer/testis antigens in women diagnosed with invasive 
ductal breast cancer and determine the expression of HER-2 antigen.
Methods The expression of MAGE-A4, NY-ESO-1, and HER-2 antigens 
was evaluated immunohistochemically on archival paraffin-embedded sam-
ples of breast cancer tissue from 81 patients. All patients had T1 to T3, N0 
to N1, M0 tumors and underwent postoperative radiotherapy and, if indi-
cated, systemic therapy (chemotherapy and hormonal therapy). The antigen 
expression in women who were disease-free for 5 years of follow up (n = 23) 
was compared with that in women with either locoregional relapse (n = 30) 
or bone metastases (n = 28). Patient survival after 10 years of follow up was 
assessed.
Results The three groups of women were comparable in terms of age, type 
of operation, tumor size, tumor grade, number of metastatically involved 
axillary lymph nodes, Nottingham prognostic index (NPI), progesterone 
receptor (PR) status, and adjuvant hormonal therapy. Estrogen receptors 
(ER) were positive in 13 women in the 5-year relapse-free group vs 8 in lo-
coregional relapse and 7 in bone metastases group (P = 0.032). There were 
significantly fewer women who received adjuvant chemotherapy in the 5-
year relapse-free group than in other two groups (7 vs 23 with locoregional 
relapse and 25 with bone metastases; P<0.001). This group also had a sig-
nificantly better 10-year survival (14 women vs 1 with locoregional relapse 
and 1 with bone metastases; P<0.001). The three groups did not differ in 
the NY-ESO-1 or HER-2 expression, but the number of patients expressing 
MAGE-A4 antigen was significantly lower in the group with locoregional 
relapse (P = 0.014). In all groups, MAGE-A4 antigen expression was associ-
ated with the NY-ESO-1 antigen expression (P = 0.006), but not with tu-
mor size and grade, number of metastatically involved axillary lymph nodes, 
or the ER and PR status. MAGE-A4-positive patients had a significantly 
longer survival than the MAGE-A4-negative patients (P = 0.046). This was 
not observed with NY-ESO-1 and HER-2 antigens.
Conclusion Our results suggest that the MAGE-A4 antigen may be used as 
a tumor marker of potential prognostic relevance.
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Breast cancer is the most common malignan-
cy in women (1). Its clinical course may vary 
from indolent and slowly progressive to rapidly 
metastatic disease. Identification of prognostic 
and predictive factors that reflect the biology of 
breast cancer is important for the assessment of 
prognosis and selection of patients who may be-
nefit from adjuvant and/or systemic therapy. The 
important aspects of prognostic factors suitable 
for clinical use are their availability, reproduci-
bility, and cost. In routine clinical practice, trea-
tment decisions and selection of treatment mo-
dalities for each individual patient are based on 
the standard prognostic factors, such as age (1,2), 
menopausal status (3), tumor size (1-4), tumor 
grade (3-5), steroid-hormone receptor status (1-
5), and nodal metastases (1-5).
Variability in clinical course of breast cancer is 
partly related to tumor cell growth rate and other 
features, such as invasiveness or metastatic poten-
tial. Research in molecular biology has identified 
genes and their products involved in or associa-
ted with the malignant cell transformation and 
behavior. Moreover, expression of some of these 
molecules, such as p53 (1,6,7), Ki-67 (7,8), nm23 
(1,7), catepsin D (1,7), Ep-CAM (9,10), HER-2 
(1,2,6), and urokinase-type plasminogen activa-
tor and its inhibitor (1,11), is associated with the 
patient’s prognosis. As it seems that many genes 
and molecules might be involved in malignant 
transformation and cell behavior, other additio-
nal molecules may also be tested as potential pro-
gnostic factors.
The cancer/testis (C/T) genes encode tu-
mor-associated antigens (TAA) found in vari-
ous tumors of different histological origin, but 
not in normal tissues other than testis (12,13). 
Their physiological function is unknown. Pep-
tides derived from these antigens could be used 
as targets in active immunotherapy. Analysis of 
the expression of these genes or their products in 
malignancies could also be of potential diagno-
stic and/or prognostic relevance (14,15). There-
fore, we performed a retrospective analysis of im-
munohistochemical expression of C/T antigens 
MAGE-A4 and NY-ESO 1 in women with in-
vasive breast cancer. We also analyzed the expre-
ssion of HER-2 antigen, because it has a progno-
stic and predictive role (1,16).
Patients and methods
Patients
Women who had invasive breast cancer in 
1995 and underwent postoperative adjuvant ra-
diotherapy were identified from medical docu-
mentation available at the Department of Ra-
diotherapy, University Hospital for Tumors, 
Zagreb, in 2000. Only women with comple-
te medical data and adequate tumor-tissue sam-
ples available from archival paraffin-embedded 
blocks were eligible. Women were included in 
the study if, at the moment of initial diagnosis, 
they had breast cancer without distant metasta-
ses (pT1-3pN0-1M0) for which they received 
surgical and adjuvant treatment of radiotherapy 
and, if indicated, systemic treatment (chemot-
herapy and hormonal therapy) in our Hospital. 
Women who received neoadjuvant therapy, had 
another primary cancer, or received treatment 
at an institution other than ours were excluded 
from the study. The final number of women in-
cluded in the analysis was 81. According to the 
disease status, there were three groups, as follows: 
women who had been relapse-free for five years, 
ie, from 1995 to 2000, those with locoregional 
relapse, and those with bone metastases. Almost 
all women with locoregional relapse had under-
gone repeated surgical and irradiation treatment. 
Locoregional relapse was defined as the first reco-
gnized recurrence of the disease in the chest wall, 
breast, axilla, or supraclavicular region. Women 
with bone metastases had all undergone irradia-
tion treatment. Those who were diagnosed with 
invasive breast cancer in years other than 1995 
were included in groups with locoregional and 
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metastatic disease, so that each group consisted 
of a similar number of patients.
Data collection
Medical files at the Department of Radiot-
herapy contained the data on the patients’ clini-
copathological findings, radiotherapy decisions, 
and/or treatments. Other data, such as those on 
the existence and sites of visceral organ metasta-
tic disease or previous or planned systemic tre-
atments of metastatic disease, were often not 
recorded or available for patients who were re-
ferred to the Department for radiotherapy and 
otherwise followed-up by other oncologists, sur-
geons, or general practitioners. Often, the day of 
disease relapse (locoregional or metastatic) could 
not be precisely determined. The complete data 
were collected on the date of breast cancer opera-
tion, pathological findings, and the type of adju-
vant systemic therapy.
Patient survival analysis was performed in 
2005. The survival data were also checked aga-
inst the Croatian National Cancer Registry and 
rechecked whenever possible by telephone calls 
to patients presumed to be alive. The study pro-
tocol was approved by the Ethics Committee of 
the Hospital and informed consent was obtained 
from all patients included in the study.
Clinicopathological features
Clinicopathological and laboratory data in-
cluded age, year of diagnosis, type of surgery, me-
dian time to disease relapse, tumor size, histo-
logical grade, axillary node status, Nottingham 
Prognostic Index (NPI) (17), estrogen and pro-
gesterone receptor positivity, administration of 
adjuvant chemotherapy or of adjuvant tamoxi-
fen, and patient survival (Table 1).
Pathological examination of primary tumors 
and axillary lymph nodes was performed at the 
Department of Pathology. For routine histologi-
cal analysis, the resected tissue was fixed in 10% 
buffered formalin, embedded in paraffin, and 
stained with hematoxylin and eosin. The histo-
logical grade of tumors was determined accor-
ding to the method by Elston (18). Tumors 
were divided into three groups according to tu-
mor size (0.1-2.0 cm as pT1, 2.1-5.0 cm as pT2, 
and >5.0 cm as pT3) and the ipsilateral axillary 
lymph node status (negative lymph node as N0, 
and positive lymph node as N1) (19). NPI sco-
res were calculated according to Rampault et al 
(17), as follows: NPI = 0.2 × tumor size (cm) + 
lymph-node stage (1, 2, or 3) + histological grade 
(1, 2, or 3), where size was measured in centime-
ters; lymph node stage 1 was lymph node-nega-
tive, stage 2 was one to three positive lymph no-
des, stage 3 was more than three positive lymph 
nodes; and the scoring of histological grade was 
1 to 3 (see below). For prognostic considerati-
ons, NPI was categorized into three groups, as 
follows: low (good prognosis), NPI≤3.4; inter-
mediate (moderate prognosis), 3.4<NPI≤5.4; 
and high (poor prognosis), NPI>5.4. Concen-
trations of estrogen and progesterone receptors 
in tumor cytosol were evaluated by the dextran-
coated charcoal assay as described elsewhere (20). 
Concentration of estrogen receptors (ER) of ≥5 
fmol/mg of protein and progesterone receptors 
(PR) of ≥10 fmol/mg of protein were considered 
to be positive (20).
Adjuvant therapies were based and prescribed 
according to the University Hospital Treatment 
Protocol for Breast Cancer (unpublished docu-
ment for in-house use). Cut-off values for ER 
and PR at the University Hospital for Tumors 
(20) were less strict than usually recommended 
(10 fmol/mg of protein for ER and 20 fmol/mg 
of protein for PR) (21). Consequently, decisions 
about the adjuvant therapies were based on these 
lower cut-off values. Adjuvant radiotherapy con-
sisted of external megavoltage irradiation delive-
red from the linear accelerator (22). Adjuvant 
chemotherapy included either the CMF proto-
col (cyclophosphamide, 600 mg/m2 IV on day 
1; methotrexate, 40 mg/m2 IV on day 1; 5-flu-
orouracil, 600 mg/m2 IV on day 1) or the FAC 
protocol (5-fluorouracil, 500 mg/m2 IV on day 
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1; doxorubicine, 50 mg/m2 IV on day 1; cyclop-
hosphamide, 500 mg/m2 IV on day 1). Cycles 
were repeated every 3 weeks, for a total of 6 cyc-
les. Tamoxifen was administered as systemic hor-
monal therapy (2 × 10 mg over 5 years) (23).
Immunohistochemical analysis for MAGE-A4, 
NY-ESO-1, and HER-2
Immunohistochemical analysis of primary 
breast cancer tissue was performed in 2000. 
Expression of MAGE-A4 and NY-ESO-1 tu-
mor-associated C/T antigens in primary bre-
ast cancer tissue was determined by monoclo-
nal antibody (mAb) 57B (24) and mAb B9.8.1.1 
(25), respectively. Within our panel of monoclo-
nal antibodies, mAb 57B (23) recognized many 
MAGE-A-related gene products, including 
MAGE-A2, MAGE-A3, MAGE-A4, MAGE-
A6, and MAGE-A12 (26). In paraffin-embed-
ded specimens, however, it had been shown to 
Table 1. Characteristics of 81 women diagnosed with invasive ductal breast cancer in 1995 after 5 years of follow-up
No. of women with breast cancer
Characteristics* relapse-free (n = 23) locoregional relapse (n = 30) bone metastases (n = 28) total P†
Age at diagnosis (y):
 30-39 0 3 0  3  0.720‡
 40-49 6 7 7 20
 50-59 7 7 7 21
 60-69 6 10 12 28
 70-79 3 2 1  6
 80-89 1 1 1  3
Year of initial diagnosis 1995 (23) 1992 (1), 1993 (2), 1994 (8), 
1995 (15), 1996 (2), 1997 (2)
1995 (9), 1997 (10), 
1998 (7), 1999 (2)
Type of operation:
 mastectomy with axillary dissection 20 30 26 76  0.143
 segmentectomy with axillary dissection  3  0  2  5
Disease relapse in 2000 (median, mo)  / 18 13 <0.001
 range (mo)  / (3-49) (2-44)
Tumor size (cm):
 <2  7  7 13 27  0.200
 2-5 16 20 13 49
 >5  0  3  2  5
Histological grade:§
 I  4  3  1  8  0.521
 II 13 18 16 47
 III  6  9 11 26
Axillary lymph node status:
 0  0  4  2  6  0.203
 1-3 14 10 12 36
  ≥4  9 16 14 39
Nottingham Prognostic Index (NPI):
  ≤3.4  1  3  1  5  0.383
 3.41-5.4 14 11 16 41
 >5.4  8 16 11 35
Estrogen receptor (fmol/mg):
 <5 10 22 21 53  0.032
  ≥5 13  8  7 28
Progesterone receptor (fmol/mg):
 <10  8 15  8 31  0.225
  ≥10 15 15 20 50
Adjuvant chemotherapy CMF/FAC 6/1 20/3 16/9 42/13 <0.001
Adjuvant tamoxifen 12 10 12 34  0.385
5-y survival:
 alive 23  7  2 32 <0.001
 dead  – 18 22 40
 unknown  –  5  4  9
10-y survival:
 alive 14  1  1 16 <0.001
 dead  7 24 23 54
 unknown  2  5  4 11
*Abbreviations: CMF – cyclophosphamide, methotrexate, 5-fluorouracil; FAC – 5-fluorouracil, doxorubicine, cyclophosphamide.
†Pearson χ2 test for all values except time to disease relapse and 5-year survival (F test within analysis of variance test).
‡P value refers only to 40-69-year age groups, because other age groups had cell frequencies <5.
§Histological grading according to the method by Elston (18).
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predominantly recognize MAGE-A4 TAA (27). 
Monoclonal antibody B9.8.1.1 is specific to NY-
ESO-1 TAA (25). Briefly, tissue sections from 
paraffin-embedded breast tumor samples (0.5 
mm thick) were placed on Silane (3-aminopro-
pyltriethoxysilane, A 3648, Sigma, St Louis, MO, 
USA)-treated microscope glass slides. After depa-
raffinization, the sections were heated in a 800W 
household microwave oven at a maximum power 
for 8.5 and 5 minutes in 10 mmol/L citric buffer 
(pH 6.0) and washed with phosphate buffered 
saline (PBS; pH 7.2). The sections were treated 
by H2O2 to suppress endogenous peroxidase ac-
tivity. After an additional PBS wash, the sections 
were incubated for 20 minutes with 1:10 diluted 
normal rabbit sera (DAKO X0902, DAKO A/
S, Copenhagen, Denmark) at room temperatu-
re in a humidified chamber to prevent nonspeci-
fic immunoglobulin binding. The sections were 
then treated with mAb 57B or mAb B9.8.1.1., in 
the form of undiluted hybridoma supernatant, 
for 90 minutes at room temperature. A streptoa-
vidin-biotinylated horseradish peroxidase-based 
detection system (DAKO K 0355) was used to 
reveal specific binding (28,29).
Immunoreactivity for MAGE-A4 and NY-
ESO-1 was scored in the following way: 0, no po-
sitive tumor cells (negative); 1+, <20% positive 
tumor cells (“mild reaction”); 2+, 21-50% posi-
tive tumor cells (“moderate reaction”); and 3+, 
>50% positive tumor cells (“strong reaction”). 
Non-neoplastic cells, such as normal ductal epi-
thelial cells and fibroblasts, were indeed present 
in all specimens but were not stained, and thus 
served as internal negative controls (28,29). The 
immunoreactivity scores were presented as either 
“negative” or “positive,” with positive including 
mild, moderate, and strong reactions.
DAKO Hercep TestTM kit was used for 
HER-2 immunohistochemical staining in accor-
dance with manufacturer’s instructions. The 
monoclonal antibody in the DAKO Hercep 
TestTM kit is approved by Food and Drug Ad-
ministration as the specific reagent for the HER-
2 detection. Samples with 3+ staining intensi-
ty score (standard control slides were included 
in the Hercep TestTM kit) were considered to be 
HER-2 positive. When Hercep test scoring sy-
stem was used, a strong positive reaction implied 
a complete (diffuse) membrane staining in >10% 
of tumor cells (16).
Statistical analysis
STATISTICA 6.1 software package (Stat-
Soft Inc., Tulsa, OK, USA) was used for all sta-
tistical analyses. Differences in time to disease re-
lapse and 5-year survival were tested by one way 
analysis of variance (ANOVA). Pearson χ2 test 
was applied for other clinicopathologic and im-
munohistochemical parameters represented as 
qualitative values. Kaplan-Meier survival method 
was used for the construction of survival proba-
bility curves, and Gehan’s Wilcoxon test for the-
ir comparison. P value of <0.05 was considered 
statistically significant.
Results
Most women were diagnosed with breast 
cancer in 1995 and most underwent modified 
radical mastectomy (Table 1). In the group of 
women with locoregional disease relapse, the me-
dian time to disease relapse was 18 months (ran-
ge, 3-49), which was significantly longer than 13 
months (range, 2-44) in the group with bone 
metastases (P<0.001). The three groups of pati-
ents did not differ in the standard clinical para-
meters except for ER status (P = 0.032) and adj-
uvant chemotherapy (P<0.001). In the 5-year 
relapse-free group, significantly more women 
had positive ER and significantly fewer received 
adjuvant chemotherapy; this group had a signi-
ficantly better survival outcome (P<0.001). In 
2005, 14 out of 23 women in this group were ali-
ve (with 2 women of unknown survival status), 
whereas in other two groups, only one women 
from each group was alive.
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Immunohistochemical results
Immunohistochemical staining of C/T pro-
teins, MAGE-A4 and NY-ESO-1, was predo-
minantly visible as cytoplasmic staining limited 
to tumor cells (Figure 1A and 1B). HER-2 sta-
ining was visible as membrane staining (Figure 
1C). Overall, positivity of mAb 57B and mAb 
B9.8.1.1 was found in 60 (74%) and 32 (40%) 
out of 81 women included in the study, respec-
tively. The expression of MAGE-A4 antigen was 
detected in a significantly fewer women with lo-
coregional relapse (P = 0.014; Table 2). Furt-
her analysis showed significant difference only in 
MAGE-A4 expression between the women with 
locoregional relapse and 5-year relapse-free group 
(P = 0.005). The expression of MAGE-A4 did 
not significantly differ between patients with lo-
coregional relapse and those with bone metasta-
ses (P = 0.076). No significant difference was fo-
und in NY-ESO-1 antigen expression between 
the three groups of women. Positive HER-2 re-
action was found in 18 out of 81 patients (22%), 
with equal distribution in all three groups.
Survival of patients was also analyzed with 
respect to the expression of MAGE-A4, NY-
ESO-1, and HER-2 antigen. It was found that 
MAGE-A4-positive patients had a significantly 
better survival than MAGE-A4-negative patients 
(P = 0.046; Figure 2). In contrast, NY-ESO-1 
and HER-2 antigen expression did not correlate 
with survival (data not shown).
Relation of MAGE-A4 antigen to the standard 
prognostic and predictive factors
Since the three groups of women with bre-
ast cancer significantly differed in MAGE-A4 
antigen expression, we analyzed the relationship 
between MAGE-A4 antigen and standard pro-
gnostic and predictive factors (Table 3). MAGE-
A4 antigen expression was found to be associated 
to a significant degree only with the NY-ESO-1 
antigen expression (P = 0.006), but not with tu-
mor size and grade, number of metastatically in-
volved axillary lymph nodes, or ER and PR sta-
tus. Such results suggest that in our patients, 
MAGE-A4 antigen might have behaved as a pro-
Figure 1. Immunohistochemical staining in invasive ductal breast can-
cer tissue. A. Intense cytoplasmic MAGE-A4 staining with monoclonal 
antibody (mAb) 57B observed in the absence of staining of normal ducts 
(peroxidase anti-peroxidase [PAP], ×400). B. NY-ESO-1 positivity with 
specific cytoplasmic tumor distribution detected by mAb B9.8.1.1 (PAP, 
×400). C. Overexpression of HER-2 detected by Hercep test, with strong 
complete membrane staining in >10% of tumor cells, noticed as a strong 
immunohistochemical reaction (PAP, ×400).
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gnostic factor unrelated to the above standard 
prognostic and predictive factors.
Discussion
This retrospective study showed that the wo-
men with breast cancer who were disease-free for 
5 years, those with locoregional relapse of the di-
sease, and those with bone metastases differed in 
MAGE-A4 expression, but not in NY-ESO-1 
and HER-2 expression. The three groups of wo-
men were comparable in clinicopathologic pa-
rameters, except for ER status and adjuvant sy-
stemic cytotoxic therapy. A significantly higher 
number of women with positive ER in the gro-
up of disease-free patients confirmed the positi-
ve prognostic and predictive role of ER. On the 
one hand, a significantly smaller number of wo-
men in this group received adjuvant chemothera-
py, which was probably caused by higher propor-
tion of ER positive cases, but on the other, there 
was no difference in adjuvant tamoxifen therapy 
between the three groups.
The biological course of the disease was prob-
ably not much influenced by the adjuvant che-
motherapy and hormonal therapy in the wom-
en with locoregional relapse and those with bone 
metastatic disease. There were fewer women with 
positive MAGE-A4 antigen staining in the group 
with locoregional relapse than in the 5-year re-
lapse-free group. No association was found be-
tween the MAGE-A4 immunohistochemical 
expression and standard prognostic and predic-
tive markers. However, a link with the NY-ESO-
1 immunohistochemical expression was found, 
which corresponds with previous findings of 
usually frequent concomitant expression of these 
two C/T antigens (13,30). Patients with positive 
and those with negative MAGE-A4 expression 
significantly differed in survival. Given the prog-
nostic and predictive role of the HER-2 antigen, 
we would expect a similar difference in survival 
with respect to its expression (7,8,14), but it was 
Table 2. Immunohistochemically detected expression of HER-2, MAGE-A-4, and NY-ESO-1 antigens in 81 women with invasive ductal 
breast cancer
No. (%) of women with breast cancer
Antigen relapse-free for 5 y (n = 23) locoregional relapse (n = 30) bone metastases (n = 28) total P*
HER-2:
 negative (0, 1+, 2+) 19 (83.0) 23 (77.0) 22 (79.0) 64 (79.0) 0.868
 positive (3+)  4 (17.0)  7 (23.0)  6 (21.0) 17 (21.0)
MAGE-A4:†
 negative (0)  2 (9.0) 13 (43.0)  6 (21.0) 21 (26.0) 0.014‡
 positive (1+, 2+, 3+) 21 (93.0) 17 (57.0) 22 (79.0) 60 (74.0)
NY-ESO-1:†
 negative (0) 13 (57.0) 22 (73.0) 14 (50.0) 49 (60.0) 0.173




‡Comparison of data between locoregional group and 5-year relapse-free group (P = 0.005) and between locoregional group and group of patients with bone metasta-
ses (P = 0.076).
Figure 2. Overall survival of 81 women with invasive ductal breast cancer 
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not detected. These results suggest that MAGE-
A4, along with traditional prognostic factors, 
could have a prognostically independent rele-
vance in patients with breast cancer.
Breast cancer biology is complex, with multi-
ple factors contributing to the development and 
growth of cancer and its metastatic progression. 
Clinical data from follow-up studies and studies 
of the biology of breast cancer could be used to 
identify parameters that could serve as prognostic 
or predictive factors. Treatment decision making 
is usually based on a combination of clinical fea-
tures and tumor characteristics, such as age, tu-
mor size, histological type and grade, lymph node 
status, and ER and PR status (1-5). However, 
since the prognostic value of these criteria is vari-
able, it is obvious that additional and still uniden-
tified molecular factors influence and determine 
the clinical course of breast cancer. By identifying 
these additional factors, therapeutic approaches 
to patients with breast cancer could be further in-
dividualized, thus increasing both the survival rate 
and quality of life of the patients. Novel high-per-
formance screening methods, such as the DNA 
microarray, which can analyze simultaneously 
the expressions of thousands of genes in a tissue 
in a single experiment, may allow the identifica-
tion of disease subsets that correlate with clinical 
outcomes. Clearly, such gene-expression profil-
ing (holistic approach), although not yet routine-
ly used in clinical practice, would provide highly 
useful prognostic information (6-11).
Immunohistochemical detection of HER-
2 antigen expression was used as the control for 
detection of MAGE-A4 and NY-ESO-1 expres-
sion. HER-2 molecule belongs to a family of four 
homologous receptors involved in the tyrosine 
kinase-mediated regulation of normal breast tis-
sue growth and development. Overexpression of 
HER-2 molecule in breast cancer cells is associat-
ed with poor prognosis (7,8,16).
C/T TAA antigens were discovered in the 
1990s, initially as targets in CD8 T-cell recogni-
tion of autologous human melanoma cells (31). 
To date, 44 C/T genes have been identified and 
their expression in numerous cancer types has 
been studied. The antigen is expressed in nor-
mal tissues, but seems to be restricted to testis, fe-
tal ovary, and placenta, and in cancers of diverse 
origin. Up to 30-40% of many different cancer 
types, eg, melanoma, bladder cancer, and sarco-
ma, express one or more C/T antigens. X chro-
mosome codes for the majority of C/T antigens; 
however, many recently defined C/T coding 
genes have non-X chromosomal loci. The func-
tion of most C/T antigens is unknown, although 
they seem likely to have some role in regulating 
gene expression. The global demethylation asso-
ciated with certain cancers might account for the 
aberrant C/T expression in cancer. Another im-
portant issue is whether the expression of these 
Table 3. Relation of MAGE-A4 expression detected by immuno-
histochemistry with tumor size, histological grade, axillary lymph 
node status, estrogen and progesteron receptor positivity, and 
HER-2 and NY-ESO-1 expression*





(1+, 2+, 3+) total P†
Tumor size (cm):
 <2  8 19 27 0.601
 2-5 11 38 49
 >5  2  3  5
Histological grade:‡
 I  2  6  8 0.911
 II 13 34 47
 III  6 20 26
Axillary lymph nodes:
 negative  3  3  6 0.369
 positive 18 57 75
Estrogen receptors 
(fmol/mg):
 <5 17 36 53 0.082
  ≥5  4 24 28
Progesterone 
receptors (fmol/mg):
 <10 10 21 31 0.306
  ≥10 11 39 50
HER-2:
 negative (0, 1+, 2+) 19 44 63 0.134
 positive (3+)  2 16 18
NY-ESO-1:
 negative (0) 18 31 49 0.006
 positive (1+, 2+, 3+)   3 29 32





‡Histological grading according to the method by Elston (18).
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genes in the cancer cell contributes to its malig-
nant behavior. There is increasing evidence that 
C/T expression is correlated with tumor pro-
gression and takes place in tumors of higher ma-
lignant potential (12,13,30).
The expression of C/T genes has mostly been 
studied on clinical material by use of polymerase 
chain reaction (PCR). However, PCR cannot 
show if the analyzed genes are expressed only in 
low percentage of tumor cells or in most of them. 
Therefore, clinical immunotherapy studies and 
trials should be aimed at antigens expressed in 
most – preferably all – tumor cells. Studies of 
therapeutic relevance are those where it is possi-
ble to quantify tumor cells expressing tumor an-
tigens, such as immunohistochemical studies, 
which can be performed today because of the de-
velopment of serological reagents (mAbs) against 
C/T TAA (13,30).
Expression of MAGE genes in breast cancers 
was reported by several groups (32-34), as well as 
particular MAGE-A1, -A2, -A3, -A4, -A6, and -
A12 specific transcripts (35), whereas much less 
has been published on their immunodetection 
(30). Kavalar et al (28) reported a correlation be-
tween mAb 57B staining and the tumor grade, 
lymphatic vessel invasion, and intratumoral ne-
crosis and an inverse correlation with ER staining.
Since this study was a preliminary investiga-
tion, the number of patients was relatively small, 
which may represent a limitation. Also, a small 
sample might be a possible reason why we did 
not observe the influence of HER-2 expression 
on patients’ survival. Therefore, potential differ-
ences in unknown factors in our, relatively small, 
patient groups may have lead to biased results or 
conclusions. Accordingly, the observation that 
the MAGE-A4 antigen has a prognostic role 
is only an initial hypothesis that should be test-
ed on a much greater number of patients with 
breast cancer.
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